CTOs on the Move

Molecular Bio-Products

www.mbpinc.com

 
We deliver the industry's broadest selection of analytical instruments, equipment, consumables and laboratory supplies. Our growing portfolio of products includes innovative technologies for mass spectrometry, elemental analysis, molecular spectroscopy,
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.mbpinc.com
  • 9389 Waples St
    San Diego, CA USA 92121
  • Phone: 800.995.2787

Executives

Name Title Contact Details

Similar Companies

Alternate Health

Alternate Health (CSE: AHG, OTCQB: AHGIF) an international leader in the hemp-derived CBD industry, including extraction, product development and distribution. Alternate Health`s industry-leading software systems provide the platform for the company`s diverse operations, including blockchain tax collection systems, hemp-derived CBD product distribution, extract manufacturing and patient management systems for specialty clinics across North America. Through Alternate Health`s subsidiary, Blaine Labs, the Company is a leader in cGMP medical product manufacturing and distribution, with over 50 product SKUs available from major retailers, including Walmart, Amazon, CVS and Walgreens. Alternate Health`s corporate office is located in Toronto, Canada, with additional offices in Venice, California, and San Antonio, Texas. The Company is well positioned to reinvest internal operating cash flow in its platform and product development over the long term, creating an attractive investment profile for its shareholders.

EBD Group

EBD Group is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GWARC

GWARC, Inc. is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valley Health Care System

Valley Health Care System is a Columbus, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.